A massive genetic study found that naturally lower cholesterol is linked to a dramatically reduced risk of dementia. The ...

Two widely available medicines can safely improve brain health in those with early Alzheimer’s disease, a new study has found ...

The team found a notable correlation between genetics that predicted low cholesterol and a lower risk of dementia, suggesting ...

The drug, lecanemab, was approved by Health Canada this week. It is the first treatment available in Canada to focus on the ...

Lecanemab is the first medication approved in Canada that targets the buildup of amyloid plaque in the brain, which is ...

Michael Borrie, physician and medical director of the Aging and Memory Clinic at St. Joseph’s Health Care London, said Health ...

Phase 3 clinical trial results of an investigational drug has shown benefits in treating people with APOE4/4 with early ...

TORONTO — Health Canada has authorized a drug shown to slow the progression of Alzheimer's disease. Lecanemab is the first ...

Controversial anti-amyloid therapies costing up to $32,000 annually offer modest hope for Alzheimer's patients while carrying ...

Having lower cholesterol levels may help protect against dementia, according to a large-scale international study led by the ...

For the first time, Health Canada has approved a new drug that targets the underlying cause of early-onset Alzheimer's disease. As health reporter Katherine Ward explains, doctors say this marks a ...

However, lecanemab doesn’t stop the relentless march of Alzheimer’s disease, it just slows it down. The medication, sold under the brand name Leqembi, also comes with a hefty price tag and a risk of ...